HER2-positives und metastasiertes Mammakarzinom: Standards und neue Entwicklungen

TY - JOUR

T1 - HER2-positives und metastasiertes Mammakarzinom: Standards und neue Entwicklungen

AU - Fehm, Tanja

AU - Müller, Volkmar

N1 - Publisher Copyright: © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - With the development of the monoclonal antibody trastuzumab against HER2, a significant breakthrough was achieved in the treatment of metastatic HER2-positive breast cancer. In the years that followed, dual blockade with the antibodies trastuzumab and pertuzumab in combination with taxane-containing chemotherapy resulted in a further significant improvement in both the metastatic and adjuvant treatment situation. The relevant literature was evaluated. T‑DM1, which is an antibody–drug conjugate comprising trastuzumab and mertansine, has further increased survival in the metastatic situation after trastuzumab compared to the former second-line treatment standard capecitabine/lapatinib. New drug developments include tyrosine kinase inhibitors such as neratinib and tucatenib as well as innovative antibody–drug conjugates including trastuzumab–deruxtecane. As various new substances are currently being evaluated, patients should be included in treatment studies whenever possible.

AB - With the development of the monoclonal antibody trastuzumab against HER2, a significant breakthrough was achieved in the treatment of metastatic HER2-positive breast cancer. In the years that followed, dual blockade with the antibodies trastuzumab and pertuzumab in combination with taxane-containing chemotherapy resulted in a further significant improvement in both the metastatic and adjuvant treatment situation. The relevant literature was evaluated. T‑DM1, which is an antibody–drug conjugate comprising trastuzumab and mertansine, has further increased survival in the metastatic situation after trastuzumab compared to the former second-line treatment standard capecitabine/lapatinib. New drug developments include tyrosine kinase inhibitors such as neratinib and tucatenib as well as innovative antibody–drug conjugates including trastuzumab–deruxtecane. As various new substances are currently being evaluated, patients should be included in treatment studies whenever possible.

KW - Antibodies, monoclonal, humanized

KW - Molecular targeted therapy

KW - Protein-tyrosine kinases

KW - Receptor ErbB‑2

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85079607709&partnerID=8YFLogxK

U2 - 10.1007/s00761-020-00724-7

DO - 10.1007/s00761-020-00724-7

M3 - SCORING: Review

AN - SCOPUS:85079607709

VL - 26

SP - 518

EP - 523

JO - ONKOLOGE

JF - ONKOLOGE

SN - 0947-8965

IS - 6

ER -